Insmed Inc. (INSM)
Insmed: "Strong Buy" As Possible Label Expansion For ARIKAYCE Bodes Well
Insmed (INSM) remains a "Strong Buy", driven by positive phase 3b ENCORE results for ARIKAYCE in 1st-line MAC lung disease and robust pipeline progress. INSM is positioned to expand ARIKAYCE's label to 1st-line MAC patients [200k+], convert accelerated to full approval for refractory MAC, and pursue Japanese label expansion. BRINSUPRI is approved for non-cystic fibrosis bronchiectasis, with 2026 revenue guidance of at least $1 billion; ARIKAYCE 2025 sales reached $433.8 million, up 19% YoY.
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study
Insmed stock jumps as Arikayce meets key goals in a late-stage study, paving the way for label expansion and a major boost to its potential market.
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript
Insmed shares rise on positive late-stage trial results for lung disease therapy
Insmed Incorporated (NASDAQ:INSM) shares jumped almost 8% in early trade on Monday after the company reported positive topline results from a Phase 3b study evaluating its lung disease therapy ARIKAYCE. The ENCORE trial assessed ARIKAYCE (amikacin liposome inhalation suspension) in combination with standard multidrug therapy versus placebo plus multidrug therapy in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection who had not previously received antibiotics.
506,245 Shares in Insmed, Inc. $INSM Bought by Bank of Nova Scotia
Bank of Nova Scotia purchased a new stake in shares of Insmed, Inc. (NASDAQ: INSM) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 506,245 shares of the biopharmaceutical company's stock, valued at approximately $72,904,000. Bank of
Aquatic Capital Management LLC Has $10.99 Million Stake in Insmed, Inc. $INSM
Aquatic Capital Management LLC trimmed its stake in Insmed, Inc. (NASDAQ: INSM) by 61.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 76,343 shares of the biopharmaceutical company's stock after selling 123,591 shares during the quarter. Aquatic Capital Management LLC's
Algert Global LLC Purchases 62,802 Shares of Insmed, Inc. $INSM
Algert Global LLC boosted its position in shares of Insmed, Inc. (NASDAQ: INSM) by 76.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 144,726 shares of the biopharmaceutical company's stock after acquiring an additional 62,802 shares during the period. Algert
Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View
INSM shares jump 7% as Brinsupri sales surge and 2026 outlook calls for at least $1B, despite a wider Q4 loss and rising expenses.
Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Insmed (INSM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Insmed (INSM) Reports Q4 Loss, Lags Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.32 per share a year ago.
